


[DRAWINGS]

[FIG. 1]




[FIG. 2]



Normal, Vehicle
ELA, Vehicle
Roflumilast
Triple conjugate


Mean linear intercept (% vs. normal)
250
200
150
100
50
**
*
Normal, Vehicle control group
ELA 0.2 U/head, Vehicle control group
ELA 0.2 U/head, Roflumilast 10 mg/kg, QD
ELA 0.2 U/head, Long-acting conjugate of triple agonist 6.5 nmol/kg, Q2D


[FIG. 3]


α-SMA
Col1α1
Fibronectin
Relative expression level (fold increase)
p=0.056
Vehicle control group (negative control)
TGF-β1 10 ng/mL only treatment group
TGF-β1 10 ng/mL + Long-acting conjugate of triple agonist 10 μM


[FIG. 4]


Col1α1
Col3α1
Relative expression level (fold increase)
Vehicle control group (negative control)
TGF-β1 5 ng/mL + LPS 0.1 μg/mL treatment group
Long-acting conjugate of triple agonist 10μM + TGF-β1 5 ng/mL + LPS 0.1 μg/mL treatment group

[FIG. 5]


Normal
BLM control
Triple conjugate
Pirfenidone
Ambroxol
MT stained positive area
(Relative fold increase)
0
1
2
3
4
5
***
***
**
***
Normal, Vehicle control group
BLM 1.5 U/kg, Vehicle control group
BLM 1.5 U/kg, Long-acting conjugate of triple agonist 2.6 nmol/kg, Q2D
BLM 1.5 U/kg, Pirfenidone 300 mg/kg, QD
BLM 1.5 U/kg, Ambroxol 45 mg/kg, QD

[FIG. 6]


120
100
80
60
40
20
0
Survival rate (%)
0
3
6
7
9
12
15
18
21
Time (days after BLM treatment)
Normal, Vehicle control group
BLM 3.0 U/kg, Vehicle control group
BLM 3.0 U/kg, Long-acting conjugate of triple agonist 2.6 nmol/kg, Q2D
BLM 3.0 U/kg, Pirfenidone 300 mg/kg, QD
BLM 3.0 U/kg, Ambroxol 45 mg/kg, QD